Wungki Park

37PUBLICATIONS
272CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisCancer geneticsPacific Peoples cultural determinants of health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Aug 11, 2026
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

|Jul 20, 2026
Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond.

|Jul 01, 2026
Pancreatic Cancer: Translating Tumor Biology into Actionability.

|Jun 26, 2026
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

|May 06, 2026
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

|Mar 27, 2026
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer.

Wungki Park, Shigeaki Umeda, Marc Hilmi

Pageof 7

Frequent Collaborators

27 joint publications

Eileen O'Reilly

13 joint publications

Alice Wei

11 joint publications

Christine Iacobuzio-Donahue

9 joint publications

Kevin Soares